Activated AKT phosphorylates TSC1/2 and relieves its inhibition function on mTORC1, promoting protein translation. AKT also phosphorylates and inhibits GSK3β, initiating glucose metabolism and ...

Tuberous Sclerosis Complex (TSC) is a genetic disorder that occurs in 1 out of 6,000 people and can involve multiple organs in the body, including the brain, heart, kidneys, lungs, eyes, and skin. The ...

While nab-sirolimus showed monotherapy activity in the study population, the trial fell short of delivering what we believe would be required to support an accelerated approval in the broad TSC1/TSC2 ...

The company had been investigating the approved mTOR inhibitor, also known as nab-sirolimus, in the midstage PRECISION1 study in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 ...

Our data verified that ANRIL could regulate the proliferation and cisplatin resistance of retinoblastoma cells through activating cell autophagy by promoting the expression of tuberous sclerosis ...

It occurs due to a variation in either the TSC1 or TSC2 gene. Neurofibromatosis refers to three different conditions. These conditions are neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and ...

TSC is caused by genetic mutations on either the TSC1 or TSC2 gene. A mutation of either of these genes leads to abnormal development and exponential growth of cells within the body. The TSC1 gene ...

Treatment with nab-Sirolimus demonstrated promising response rates in patients with gynecologic PEComa, according to a subgroup analysis of the phase 2 AMPECT study. Nab-sirolimus (Fyarro; ABI-009) ...

Among patients with TSC2 mutations, 2 achieved a CR, 6 had a PR, and 1 had SD. Among patients with TSC1 mutations, there were no CRs, 1 PR, and 3 cases of SD. The median progression-free survival ...

The oligomeric NPM1 recruited histone demethylase KDM5b to the promoter of Tsc1 (TSC complex subunit 1), the mTOR (mechanistic target of rapamycin kinase) complex inhibitor, reduced histone H3K4me3 ...